Database : HANSEN
Search on : ADJUVANTES IMUNOLOGICOS/FARMACOL [Subject descriptor]
References found : 3 [refine]
Displaying: 1 .. 3   in format [Detailed]

page 1 de 1

  1 / 3 HANSEN  
              next record last record
select
to print
Id:13938
Author:Dredge, Keith; Marriott, J. Blake; Dalgleish, Angus G
Title:Immunological effects of thalidomide and its chemical and functional analogs ..-
Source:s.l; s.n; 2002. 13 p. ilus, tab.
Abstract:Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer. Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-alpha, T-cell costimulatory and antiangiogenic activity. Novel compounds with improved immunomodulatory activity and side effect profiles are also being evaluated. These include selective cytokine inhibitory drugs (SelCIDs), with greatly improved TNF-alpha inhibitory activity, and immunomodulatory drugs (IMiDs) that are structural analogs of thalidomide, with improved properties. A third group recently identified within the SelCID group, with phosphodiesterase type 4-independent activity, is in the process of being characterized in laboratory studies. This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV. We also describe the laboratory studies that have led to the characterization and development of SelCIDs and IMiDs into potentially clinically relevant drugs. Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers. Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties. (AU).
Descriptors:TALIDOMIDA/analog
TALIDOMIDA/imunol
TALIDOMIDA/farmacol
SISTEMA IMUNE/ef drogas
NEOPLASIAS/quimioter
NEOPLASIAS/imunol
INFECCOES POR HIV/quimioter
INFECCOES POR HIV/imunol
ADJUVANTES IMUNOLOGICOS/farmacol
INIBIDORES DE ANGIOGÊNESE/imunol
INIBIDORES DE ANGIOGÊNESE/farmacol
ANTIVIRAIS/imunol
ANTIVIRAIS/farmacol
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 04731/s


  2 / 3 HANSEN  
              first record previous record next record last record
select
to print
Id:10264
Author:Mazumder, Shibnath; Nath, Indira; Dhar, M. M
Title:Immunomodulation of human T cell responses with receptor selective enkephalins ..-
Source:s.l; s.n; 1993. 6 p. graf.
Descriptors:ADJUVANTES IMUNOLOGICOS
SEQUENCIA DE AMINOACIDOS
ENCEFALINA METIONINA
ENCEFALINAS
ENCEFALINAS
IMUNOSSUPRESSORES
HANSENIASE
TRANSFORMAÇAO LINFOCITICA
DADOS DE SEQUENCIA MOLECULAR
PEPTIDIOS CICLICOS
RECEPTORES OPIOIDES DELTA
RECEPTORES OPIOIDES DELTA
RECEPTORES OPIOIDES KAPPA
RECEPTORES OPIOIDES MU
RECEPTORES OPIOIDES MU
FORMAÇAO DE ROSETA
LINFOCITOS T
LINFOCITOS T
LINFOCITOS T
TUBERCULOSE PULMONAR
D-Penicilina (2,5)-Encefalina
Limits:IN VITRO
Location:BR191.1; 06943/s


  3 / 3 HANSEN  
              first record previous record
select
to print
Id:10047
Author:Mitra, D. K; Rajalingam, R; Taneja, V; Bhattacharyya, B. C; Mehra, N. K
Title:HLA-DR polymorphism modulates the cytokine profile of Mycobacterium leprae HSP-reactive CD4+ T cells ..-
Source:s.l; s.n; 1997. 8 p. tab, graf.
Descriptors:ADJUVANTES IMUNOLOGICOS
PROTEINAS DE BACTÉRIAS
LINFOCITOS T CD4-POSITIVOS
CHAPERONINAS
ANTIGENOS HLA-DR
PROTEINAS DO CHOQUE TÉRMICO
HANSENIASE
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM TUBERCULOSIS
POLIMORFISMO (GENÉTICA)
CÉLULAS TH1
CÉLULAS TH2
Location:BR191.1; 07012/s



page 1 de 1
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information